Compare iShares MSCI Australia ETF (EWA) vs Inovio Pharmaceuticals Inc (INO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI Australia ETF vs Inovio Pharmaceuticals Inc — how do they compare? iShares MSCI Australia ETF trades at $29.88, while Inovio Pharmaceuticals Inc trades at $0.77 (market cap $78.55M). The key difference: iShares MSCI Australia ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| EWA | INO | |
|---|---|---|
Sector | Broad Market / Factor | Health |
52-Week High | $30.41 | $2.87 |
52-Week Low | $24.95 | $0.66 |
Market Cap | — | $78.55M |
Enterprise Value | — | $49.56M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWA trades at $29.985, down 0.22% on the day, with a bullish technical signal from moving averages and strong trend strength indicated by ADX readings. The stock shows neutral momentum oscillators, and support/resistance levels are consolidated around $30. A dividend of $0.40 is scheduled for June 2026, providing income potential.
Outlook remains cautiously optimistic given technical strength, but fundamental data is unavailable for valuation assessment. Risks include reliance on Australian economic conditions and sector-specific headwinds. Investors should seek updated financials for a complete view amid mixed sentiment.
INO trades at $0.76, up 2.74% today, but remains in a bearish technical trend. The company shows minimal revenue of $65K against high operating losses, with a net income margin of -130,000%. Recent quarterly EPS has beaten expectations. Analyst consensus is bullish with a $3.25 price target, but the stock faces significant fundamental challenges including negative cash flow and high valuation multiples.
The outlook hinges on FDA approval of INO-3107 in October 2026, a binary event that could drive substantial upside. However, persistent cash burn, negative profitability, and ongoing shareholder litigation present high risks. Investors should weigh the potential catalyst against the company's weak financial health and operational execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About iShares MSCI Australia ETF
EWA tracks the MSCI Australia Index, providing broad exposure to large and mid-cap companies in the Australian equity market. It is structurally dominated by the financial and materials sectors, serving as a key instrument for investors seeking a single-country view of Australia's resource-rich and stable economy.
Read more on EWA →About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →
